Advertisement


Stephen M. Ansell, MD, PhD, on Precision Immunotherapy for Refractory Hodgkin Lymphoma

2016 Pan Pacific Lymphoma Conference

Advertisement

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the role of checkpoint inhibitors in Hodgkin lymphoma and the efficacy of nivolumab and pembrolizumab.



Related Videos

Lymphoma

Nathan Fowler, MD, and Sagar Lonial, MD, on Treating Follicular Lymphoma

Nathan H. Fowler, MD, of University of Texas MD Anderson Cancer Center, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss managing early relapsing/refractory disease.

Lymphoma

Wyndham H. Wilson, MD, PhD, on Treating Diffuse Large B-Cell Lymphoma

Wyndham H. Wilson, MD, PhD, of the National Cancer Institute, discusses the molecular underpinnings of diffuse large B-cell lymphoma and targeted treatments.

Multiple Myeloma

Beth M. Faiman, PhD, MSN, CNP, AOCN, on Managing Multiple Myeloma

Beth M. Faiman, PhD, MSN, CNP, AOCN, of the Cleveland Clinic, discusses working with patients with multiple myeloma to minimize the toxicity of their treatment and improve their outcomes.

Julie M. Vose, MD, MBA, on Basket Trials

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses this evolution of clinical trials, and using genomic methods to direct therapy.

Lymphoma

Fredrick B. Hagemeister, Jr, MD, on Using Rituximab Maintenance

Fredrick B. Hagemeister, Jr, MD, of the University of Texas MD Anderson Cancer Center, discusses whether rituximab maintenance should be used in indolent lymphomas other than follicular.

Advertisement

Advertisement




Advertisement